Лиза Хендриксон-Джек - Пятый элемент здоровья. Как использовать менструальный цикл для поддержания жизненно важных функций организма

56. Hobart, Julie A., and Douglas R. Smucker. “The female athlete triad.” American Family Physician 61, no. 11 (2000): 3357–3364.

57. Deimel, Jay F., and Bradley J. Dunlap. “The female athlete triad.” Clinics in Sports Medicine 31, no. 2 (2012): 247–254.

58. Ong, Jun Liang, and Iain A. Brownlee. “Energy expenditure, availability, and dietary intake assessment in competitive female dragon boat athletes.” Sports 5, 45, no. 2 (2017): 1–7.

59. Cialdella-Kam, Lynn, Charlotte P. Guebels, Gianni F. Maddalozzo, and Melinda M. Manore. “Dietary intervention restored menses in female athletes with exercise-associated menstrual dysfunction with limited impact on bone and muscle health.” Nutrients 6, no. 8 (2014): 3018–3039.

60. Biller, Beverly M.K., Howard J. Federoff, James I. Koenig, and Anne Klibanski. “Abnormal cortisol secretion and responses to corticotropin-releasing hormone in women with hypothalamic amenorrhea.” The Journal of Clinical Endocrinology & Metabolism 70, no. 2 (1990): 311–317.

61. Hergenroeder, Albert C. “Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults.” The Journal of Pediatrics 126, no. 5 (1995): 683–689.

62. Cann, Christopher E., Mary C. Martin, Harry K. Genant, and Robert B. Jaffe. “Decreased spinal mineral content in amenorrheic women.” JAMA 251, no. 5 (1984): 626–629.

63. Hergenroeder, Albert C. “Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults.” The Journal of Pediatrics 126, no. 5 (1995): 683–689.

64. Berger, Claudie, David Goltzman, Lisa Langsetmo, Lawrence Joseph, Stuart Jackson, Nancy Kreiger, Alan Tenenhouse, K. Shawn Davison, Robert G. Josse, Jerilynn C. Prior, and David A. Hanley. “Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis.” Journal of Bone and Mineral Research 25, no. 9 (2010): 1948–1957.

65. Hergenroeder, Albert C., E. O’Brian Smith, Roman Shypailo, Lovell A. Jones, William J. Klish, and Kenneth Ellis. “Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months.” American Journal of Obstetrics and Gynecology 176, no. 5 (1997): 1017–1025.

66. Warren, Michelle P., Jeanne Brooks-Gunn, Richard P. Fox, Claire C. Holderness, Emily P. Hyle, William G. Hamilton, and Linda Hamilton. “Persistent osteopenia in ballet dancers with amenorrhea and delayed menarche despite hormone therapy: a longitudinal study.” Fertility and Sterility 80, no. 2 (2003): 398–404.

67. Altayar, Osama, Alaa Al Nofal, B. Gisella Carranza Leon, Larry J. Prokop, Zhen Wang, and M. Hassan Murad. “Treatments to prevent bone loss in functional hypothalamic amenorrhea: a systematic review and meta-analysis.” Journal of the Endocrine Society 1, no. 5 (2017): 500–511.

1. Wiley, T.S., Julie Taguchi, and Bent Formby. (2009). Sex, Lies, and Menopause: The Shocking Truth about Synthetic Hormones and the Benefits of Natural Alternatives. New York, NY: Harper Collins.

2. Watkins, E.S. “How the pill became a lifestyle drug: The pharmaceutical industry and birth control in the United States since 1960.” American Journal of Public Health 102, no. 8 (2012): 1462–1472.

3. Liao, Pamela Verma, and Janet Dollin. “Half a century of the oral contraceptive pill: historical review and view to the future.” Canadian Family Physician 58, no. 12 (2012): e757–e760.

4. Marsh, Margaret S., and Wanda Ronner. (2008). The Fertility Doctor: John Rock and the Reproductive Revolution. Baltimore, MD: Johns Hopkins University Press, 140.

5. Roberts, William C. “Facts and ideas from anywhere: ‘The pill’ and its four major developers.” Proceedings (Baylor University Medical Centre) 28, no. 3 (2015): 421–432.

6. Chasan-Taber, Lisa, Walter C. Willett, Meir J. Stampfer, Donna Spiegelman, Bernard A. Rosner, David J. Hunter, Graham A. Colditz, and JoAnn E. Manson. “Oral contraceptives and ovulatory causes of delayed fertility.” American Journal of Epidemiology 146, no. 3 (1997): 264.

7. Lefebvre, Yves. “Anatomical and functional changes induced by oral contraception.” Canadian Medical Association Journal 102, no. 6 (1970): 622.

8. Korver, Tjeerd, Christine Klipping, Doris Heger-Mahn, Ingrid Duijkers, Gonnie van Osta, and Thom Dieben. “Maintenance of ovulation inhibition with the 75-μg desogestrel-only contraceptive pill (Cerazette®) after scheduled 12– h delays in tablet intake.” Contraception 71, no. 1 (2005): 8–13; Rice, C.F., S.R. Killick, T. Dieben, and H. Coelingh Bennink. “A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and levonorgestrel 30 μg daily.” Human Reproduction 14, no. 4 (1999): 982–985; Xiao, Bilian, Liying Zhou, Xuling Zhang, Tapani Luukkainen, and Hannu Allonen. “Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device.” Contraception 41, no. 4 (1990): 353–362.

9. Xiao, Bilian, Tao Zeng, Shangchun Wu, Hongzhu Sun, and Na Xiao. “Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.” Contraception 51, no. 6 (1995): 359–365.

10. Grow, Daniel R., and Khosro Iromloo. “Oral contraceptives maintain a very thin endometrium before operative hysteroscopy.” Fertility and Sterility 85, no. 1 (2006): 204–207; Benagiano, Giuseppe, Alessandra Pera, and Francesco M. Primiero. “The endometrium and hormonal contraceptives.” Human Reproduction 15, no. suppl 1 (2000): 101–118.

11. Hatcher, Robert Anthony, and Anita L. Nelson. (2007). Contraceptive Technology. London: Ardent Media; Nassaralla, Claudia L., Joseph B. Stanford, K. Diane Daly, Mary Schneider, Karen C. Schliep, and Richard J. Fehring. “Characteristics of the menstrual cycle after discontinuation of oral contraceptives.” Journal of Women’s Health 20, no. 2 (2011): 169–177.

12. Oliveira, J.B.A., R.L.R. Baruffi, A.L. Mauri, C.G. Petersen, M.C. Borges, and J.G. Franco. “Endometrial ultrasonography as a predictor of pregnancy in an in-vitro fertilization programme after ovarian stimulation and gonadotrophin-releasing hormone and gonadotrophins.” Human Reproduction 12, no. 11 (1997): 2515–2518; Dickey, Richard P., Terry T. Olar, Steven N. Taylor, David N. Curole, and Ellen M. Matulich. “Relationship of endometrial thickness and pattern to fecundity in ovulation induction cycles: effect of clomiphene citrate alone and with human menopausal gonadotropin.” Fertility and Sterility 59, no. 4 (1993): 756–760.

13. Oliveira, J.B.A., R.L.R. Baruffi, A.L. Mauri, C.G. Petersen, M.C. Borges, and J.G. Franco. “Endometrial ultrasonography as a predictor of pregnancy in an in-vitro fertilization programme after ovarian stimulation and gonadotrophin-releasing hormone and gonadotrophins.” Human Reproduction 12, no. 11 (1997): 2517.

14. Dickey, Richard P., Terry T. Olar, Steven N. Taylor, David N. Curole, and Ellen M. Matulich. “Relationship of endometrial thickness and pattern to fecundity in ovulation induction cycles: effect of clomiphene citrate alone and with human menopausal gonadotropin.” Fertility and Sterility 59, no. 4 (1993): 756–760; Al Mohammady, Maged, Ghada Abdel Fattah, and Mostafa Mahmoud. “The impact of combined endometrial thickness and pattern on the success of intracytoplasmic sperm injection (ICSI) cycles.” Middle East Fertility Society Journal 18, no. 3 (2013): 165–170.

15. Grow, Daniel R., and Khosro Iromloo. “Oral contraceptives maintain a very thin endometrium before operative hysteroscopy.” Fertility and Sterility 85, no. 1 (2006): 204–207; Mascarenhas, Lawrence, Agaath van Beek, H. Coelingh Bennink, and John Newton. “A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK.” Human Reproduction 13, no. 11 (1998): 3059; Benagiano, Giuseppe, Alessandra Pera, and Francesco M. Primiero. “The endometrium and hormonal contraceptives.” Human Reproduction 15, no. suppl 1 (2000): 101–118; Wright, Kristen Page, and Julia V. Johnson. “Evaluation of extended and continuous use oral contraceptives.” Therapeutics and Clinical Risk Management (2008): 905–911.

16. Hidalgo, Maria M., Creusa Hidalgo-Regina, M. Valeria Bahamondes, Ilza Monteiro, Carlos A. Petta, and Luis Bahamondes. “Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel– releasing intrauterine system.” Contraception 80, no. 1 (2009): 84–89; Lakha, F., P.C. Ho, Z.M. Van der Spuy, K. Dada, R. Elton, A.F. Glasier, H.O.D. Critchley, A.R.W. Williams, and D.T. Baird. “A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel).” Human Reproduction 22, no. 9 (2007): 2428–2436.

17. Wright, Kristen Page, and Julia V. Johnson. “Evaluation of extended and continuous use oral contraceptives.” Therapeutics and Clinical Risk Management (2008): 906.

18. Там же, 907.

19. “YAZ (Drospirenone/Ethinyl Estradiol) – Official Website.” Accessed March 18, 2017. www.yaz-us.com

20. Helmerhorst, F.M., J.P. Vandenbroucke, C.J.M. Doggen, and F.R. Rosendaal. “The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.” The BMJ 339 (2009): 1–8.

21. “Thrombosis.” Wikipedia. Accessed August 23, 2017. en.wikipedia.org/wiki/Thrombosis.

22. Hendrickson-Jack, Lisa. “FFP 007 | What the Pill Really Does to Your Hormones | PCOS & Menstrual Irregularities | Dr. Lara Briden.” Fertility Friday Podcast. Podcast Audio, January 30, 2015. fertilityfriday.com/lara

23. Castle, S., and I. Askew. “Contraceptive discontinuation: reasons, challenges, and solutions.” New York: Population Council (2015); 1–33; Berenson, Abbey B., and Constance M. Wiemann. “Contraceptive use among adolescent mothers at 6 months postpartum.” Obstetrics & Gynecology 89, no. 6 (1997): 999–1005; Westhoff, Carolyn L., Stephen Heartwell, Sharon Edwards, Mimi Zieman, Gretchen Stuart, Carrie Cwiak, Anne Davis, Tina Robilotto, Linda Cushman, and Debra Kalmuss. “Oral contraceptive discontinuation: do side effects matter?” American Journal of Obstetrics and Gynecology 196, no. 4 (2007): 412-e1; Peipert, Jeffrey F., Qiuhong Zhao, Jenifer E. Allsworth, Emiko Petrosky, Tessa Madden, David Eisenberg, and Gina Secura. “Continuation and satisfaction of reversible contraception.” Obstetrics and Gynecology 117, no. 5 (2011): 1105.

24. Castle, S., and I. Askew. “Contraceptive discontinuation: reasons, challenges, and solutions.” New York: Population Council (2015); 2–3; Westhoff, Carolyn L., Stephen Heartwell, Sharon Edwards, Mimi Zieman, Gretchen Stuart, Carrie Cwiak, Anne Davis, Tina Robilotto, Linda Cushman, and Debra Kalmuss. “Oral contraceptive discontinuation: do side effects matter?” American Journal of Obstetrics and Gynecology 196, no. 4 (2007): 412e1–412e7.

25. Westfall, John M., Deborah S. Main, and Lynn Barnard. “Continuation rates among injectable contraceptive users.” Family Planning Perspectives (1996): 275–277.

26. Test ID: TTFB Testosterone, Total, Bioavailable, and Free, Serum. TTFB – Clinical: Testosterone, Total, Bioavailable, and Free, Serum. Accessed December 21, 2017. www.mayomedicallaboratories.com/test-catalog/Clinical and Interpretive/83686.

27. Davis, Susan. “Testosterone and sexual desire in women.” Journal of Sex Education and Therapy 25, no. 1 (2000): 25–32.